In contrast, neither plasmid nor penetratin delivered dn-ATF5 appears to affect survival of non-transformed cells and there have been no evident side-effects in mice treated with either the recombinant or synthetic forms of CP-dn-ATF5 at doses that suppress tumor growth2,24,26,27. Here, ATF5 is linked to neoplasm.